Price
No data yet.
Social Signal Score
Analyst Ratings
31 analystsRevenue
$360.98M+3759.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Helmy Eltoukhy
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 2,498
- Beta
- 1.66
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.44
Financials
Revenue
$360.98M+3759.0%Net Income
$-124.36MEBITDA
$-112.50MFree Cash Flow
$-37.19MEPS (diluted)
$-0.93Shares Outstanding (diluted)
134.42M+916.5%Operating Expenses
$368.92MCash & Debt
$1.03BReturn of Capital
$0.00Revenue by Segment (annual)
$982.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $982.02M | $-416.28M | $-3.32 |
| 2024 | $739.02M | $-436.37M | $-3.56 |
| 2023 | $563.95M | $-479.45M | $-4.28 |
| 2022 | $449.54M | $-654.59M | $-6.41 |
| 2021 | $373.65M | $-405.67M | $-4.00 |
| 2020 | $286.73M | $-253.78M | $-2.53 |
| 2019 | $214.38M | $-75.65M | $-0.75 |
| 2018 | $90.64M | $-85.06M | $-1.00 |
| 2017 | $49.84M | $-83.22M | $-1.18 |
| 2016 | $25.25M | $-46.14M | $-3.49 |
Valuation
GHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
109+118.06%Social Signal Score
Mentions (32)
- News (RSS)investing·2d ago·Neutral
AI Takes On Cancer Detection From a Single Blood Draw (MEDS, ANT, GH, GRAL, NTRA, FRNM)
View source ↗ - News (Marketaux)thehindubusinessline.com·2d ago·Positive
Strand Life Sciences to take its multi-cancer blood test to more hospitals, looks to bring down cost: CEO The liquid biopsy segment has companies [+224 characters]
View source ↗ - Newsbusinesswire.com·3d ago·Neutral
Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular residual disease (MRD) platform for solid tumors offering personalized, ultra-sensitive detection of residual cancer. Built on Guardant's Smart Platform, Reveal Ultra incorporates tumor-informed, patient-specific…
View source ↗ - News (RSS)zerohedge·10d ago·Neutral
… sided with the Commission. Canada's CPPIB plans to boost its hedge fund allocation to about $160 billion. Southern Co. is offering $1.75 billion of equity units and Guardant Health priced $500 million of zero-coupon converts. Separately, Citrini's Jukan claims Nvidia's Rubin has been delayed again, with volume shipments slipping to 2027, and Axios reports Trump authorized a crackdown on companies diverting Nvidia's advanced chips to China.The global framing this morning is a simple one: a rebou…
View source ↗ - News (Marketaux)prnewswire.com·11d ago·Positive
Guardant360® Tissue Receives MOHW LDTS approval in Taiwan Approval paves the way for possible reim[+354 characters]
View source ↗ - Newsbusinesswire.com·13d ago·Positive
Guardant Health to Participate in Upcoming Investor Conferences PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 18 at 3:00 p.m. Greenwich Mean Time Piper Sandler 38th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 1 at…
View source ↗ - News (RSS)zerohedge·16d ago·Neutral
…t missed the average analyst estimate.JFrog (FROG) climbs 23% after the digital security provider predicted its fastest revenue growth in four years.Guardant Health (GH) slumps 7% after the diagnostic test maker posted reported volume growth for its Shield cancer test that analysts found short of investor expectations.IonQ (IONQ) gains 8% after the quantum computing company’s results and forecast underlined positive demand trends.Lyft (LYFT) falls 7% after the ride-hailing company gave a current…
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
What Guardant Health (GH) Said on Its Q3 Earnings Call Guardant Health NASDAQ: GH raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based cancer screening test.
View source ↗ - Newszacks.com·17d ago·Neutral
Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·18d ago·Neutral
Countdown to Guardant Health (GH) Q3 Earnings: Wall Street Forecasts for Key Metrics Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - News (RSS)seekingalpha·30d ago·Positive
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program
View source ↗ - Newsbenzinga.com·30d ago·Positive
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsmarketbeat.com·34d ago·Positive
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
View source ↗ - Newsfxempire.com·48d ago·Positive
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250 Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
View source ↗ - Newsbusinesswire.com·48d ago·Negative
…ons Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ …
View source ↗ - News (RSS)yahoo·62d ago·Neutral
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
View source ↗ - News (RSS)seekingalpha·63d ago·Positive
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
View source ↗ - News (RSS)investing·67d ago·Neutral
Cathie Wood’s ARK buys Guardant Health stock, sells Iridium
View source ↗ - Newsbusinesswire.com·74d ago·Neutral
…Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (…
View source ↗ - 4chan /biz/biz·75d ago·Negative
To 51% attack XMR the attacking pools would need to exceed 6 GH/s, which would require sustained control of 300,000 Ryzen 7950X CPUs. To purchase that hardware outright would be like $300 million + the electrical power required to run them.
View source ↗ - Newsbusinesswire.com·75d ago·Neutral
Business Insider Names Guardant Health One of America's Most Innovative Businesses PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for t…
View source ↗ - News (RSS)yahoo·75d ago·Neutral
What Makes Guardant Health (GH) a Compelling Bet?
View source ↗ - News (RSS)yahoo·78d ago·Neutral
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
View source ↗ - Newsgurufocus.com·90d ago·Neutral
Guardant Health Inc (GH) Shares Fall 4.4% -- What GF Score of 65 Tells Investors On August 24, 2026, Guardant Health Inc (GH) shares fell 4.4% to a current price of $163.18, reflecting a volatile trading environment. The stock has experience
View source ↗ - News (RSS)yahoo·90d ago·Negative
Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties
View source ↗ - Newsbusinesswire.com·90d ago·Positive
Guardant Health to Appeal Federal District Court Judgment PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal.…
View source ↗ - News (RSS)zerohedge·94d ago·Positive
…the country of Ghana where the poverty rate is 22% and the average yearly wage is $2630 USD. The one-day deal (one piece of chicken, two tenders, and a small fry for GH¢15, roughly equivalent to $1.35 US) ran from 9 AM to 5 PM at locations across Ghana. The event unexpectedly drew massive crowds with no police presence, which resulted in a stampede at multiple locations that nearly developed into riots. They opened a KFC in Africa and it goes exactly how you think it would. I’m not even making t…
View source ↗ - Newsmarketbeat.com·100d ago·Neutral
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.
View source ↗ - News (RSS)seekingalpha·102d ago·Positive
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - News (Marketaux)finance.yahoo.com·102d ago·Neutral
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million Guardant Health serves[+242 characters]
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Guardant Health: Screening And MRD Are Just Getting Started Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $-0.75 per share
Typical surprise -5.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.29 vs $-0.75beat
- Thu, Jul 30$-0.90 vs $-0.76miss
- Thu, May 7$-0.85 vs $-0.81miss
- Thu, Feb 19$-1.00 vs $-0.77miss
- Wed, Oct 29$-0.74 vs $-0.79beat
- Wed, Jul 30$-0.80 vs $-0.74miss
Estimates and results for GH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GH officers and directors.
- Bought
- —
- Sold
- $3.3m
0 trades
16 trades
- Monroe Terilyn J.sold
- Monroe Terilyn J.sold
- Monroe Terilyn J.sold
- Monroe Terilyn J.sold
- Monroe Terilyn J.sold
- Azar Alex M Iisold
- Tariq Musasold
- Tariq Musasold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Jonathan Jacksonhouse · IL01 · disclosed Oct 20, 2026 (22d later)Buy$15,001 - $50,000
- Sheldon Whitehousesenate · RI · disclosed Dec 1, 2025 (10d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Mar 3, 2022 (3d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 1, 2022 (19d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Jan 1, 2022 (10d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Dec 1, 2020 (29d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Nov 5, 2020 (14d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Nov 5, 2020 (31d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Aug 9, 2020 (26d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed May 31, 2020 (30d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed May 9, 2020 (12d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 22, 2020 (8d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
